OP White Papers - random

31. How To Maximize Pipeline Value And Enhance eNPV 6/9/2026

    Find out how reducing vendor fragmentation can improve program continuity, minimize delays, and support more predictable development outcomes.

32. Transitioning Your Product From Phase 1 To Phase 2 Clinical Studies 12/13/2024

    Strategic partnerships can streamline your transition from Phase 1 to Phase 2 clinical studies, ensuring optimized dosage forms, seamless scale-up, and alignment with patient and study requirements.

33. White Paper: Spray Drying Biologics: An Alternative To Freeze Drying 10/16/2024

    Explore how innovative drying technologies can enhance the stability and efficacy of biologics, ensuring successful outcomes in this rapidly growing sector of the pharmaceutical industry.

34. Accelerating Small Molecule Protein Degrader Development Using High-Content Imaging 5/6/2026

    High‑content imaging enables rapid discovery and optimization of small‑molecule protein degraders by delivering multiparametric, single‑cell insights that accelerate hit identification, SAR development, and lead advancement.

35. A Comprehensive Solution For Adventitious Agent Testing 2/13/2026

    Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

36. ADC Development Grows More Complex — SPR Insights Bring Clarity 4/14/2026

    Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.

37. Seasonal Vaccine Manufacturing: 3 Areas To Evaluate When Selecting A Partner 10/16/2024

    Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.

38. ADCs: Overcoming Analytical Challenges In Next-Gen Cancer Therapies 2/24/2026

    Antibody-Drug Conjugates (ADCs) represent a revolutionary approach in cancer treatment. But with innovation comes complexity. 

39. 5 Steps To Design A Microbiological Performance Qualification For Facilities 4/21/2025

    Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.

40. Manufacturing Of Cytotoxic And Non-Cytotoxic Drugs In A Multiproduct Facility 10/16/2024

    The experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.